ArticleHeart and vessels2026
Simple risk stratification of patients with ST-segment elevation myocardial infarction: based on the modified DanGer shock trial-derived criteria assessed at initial emergency room presentation.
Article in Heart and vessels, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We aimed to investigate association of three DanGer Shock trial criteria [systolic blood pressure [SBP] < 100 mmHg, lactate ≥ 2.5 mmol/L, and left ventricular ejection fraction (LVEF) < 45%] on clinical outcomes among patients with ST-elevation myocardial infarction (STEMI) in Japan and evaluate whether these criteria could serve as a simple prognostic model for risk stratification. This single-center, retrospective, observational study included 1,211 patients with STEMI who underwent percutaneous coronary intervention (PCI) between 2014 and October 2023. The primary outcome was all-cause mortality at 180 days after the index PCI. To estimate the predictor of all cause death, a multivariable logistic regression analysis was conducted, and a scoring system was developed based on the results of the analysis. Patients were stratified according to the derived scoring system, and the prognostic utility of this stratification was evaluated. Among them, 4.1% met all the 3 key inclusion criteria of the DanGer Shock trial. The overall 180-day mortality rate was 6.5%. In multivariable analysis, each of the 2 criteria (SBP < 100 mmHg and LVEF < 45%) was significantly associated with 180-day all-cause death. Based on a multivariable logistic regression model, a simple shock score was developed (SBP < 100 mmHg, 1 point; lactate ≥ 2.5 mmol/L, 1 point; and LVEF < 45%, 2 points). With higher total shock scores, 180-day mortality increased exponentially (score 0: 1.9%, score 1: 2.8%, score 2: 6.1%, score 3: 16.4%, score 4 points, 42.7%, log-rank P< 0.001). In real-world clinical practice, few patients with STEMI fulfilled the 3 key inclusion criteria of the DanGer Shock trial. The simple score based on modified DanGer Shock trial-derived criteria assessed at initial emergency room presentation effectively stratified 180-day mortality risk in patients with STEMI.
Indexed as
Identifiers
42709177What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.